Preventive effects of fasudil on adriamycin-induced cardiomyopathy: Possible involvement of inhibition of RhoA/ROCK pathway

Food and Chemical Toxicology

Volumn 49, Issue 11, 2011, Pages 2975-2982

  Wang, Na ^a   Guan, Peng ^b   Zhang, Jian Ping ^a   Chang, Yan Zhong ^b   Gu, Li Juan ^a   Hao, Fei ke ^a   Shi, Zhen Hua ^b   Wang, Feng Yun ^c   Chu, Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI NORMAL UNIVERSITY   (China)

^c General Hospital of Huabei Oil Field   (China)

Author keywords

Adriamycin; Apoptosis; Cardiomyopathy; Fasudil; RhoA ROCK

Indexed keywords

CAPTOPRIL; CREATINE KINASE; DOXORUBICIN; FASUDIL; FLICE INHIBITORY PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; GENE EXPRESSION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART PROTECTION; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; ULTRASTRUCTURE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CARDIOMYOPATHIES; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CREATINE KINASE; DOXORUBICIN; GENE EXPRESSION REGULATION; HEART; HEMODYNAMICS; LACTATE DEHYDROGENASES; MALE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER;

RATTUS;

EID: 80053561902     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.06.080     Document Type: Article

References (52)

1. Abbas S., Abu-Amer Y. Dominant-negative IκB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J. Biol. Chem. 2003, 278(22):20077-20082.
2. Bolaman Z., Cicek C., Kadikoylu G., Barutca S., Serter M., Yenisey C., Alper G. The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats. Tohoku J. Exp. Med. 2005, 207(4):249-253.
3. Chang J., Xie M., Shah V.R., Schneider M.D., Entman M.L., Wei L., Schwartz R.J. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc. Natl. Acad. Sci. USA 2006, 103(39):14495-14500.
4. Cheng H., Wang S., Jo Y.I., Hao C.M., Zhang M., Fan X., Kennedy C., Breyer M.D., Moeckel G.W., Harris R.C. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J. Am. Soc. Nephrol. 2007, 18(2):551-559.
5. Chicco A.J., Hydock D.S., Schneider C.M., Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J. Appl. Physiol. 2006, 100(2):519-527.
6. Chinenov Y., Kerppola T.K. Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity. Oncogene 2001, 20(19):2438-2452.
7. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351(Pt 1):95-105.
8. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003, 3(11):859-868.
9. Eitenmuller I., Volger O., Kluge A., Troidl K., Barancik M., Cai W.J., Heil M., Pipp F., Fischer S., Horrevoets A.J., Schmitz-Rixen T., Schaper W. The range of adaptation by collateral vessels after femoral artery occlusion. Circ. Res. 2006, 99(6):656-662.
10. Francis G.S. Pathophysiology of chronic heart failure. Am. J. Med. 2001, 110(Suppl. 7A):37S-46S.
11. Fukata Y., Amano M., Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol. Sci. 2001, 22(1):32-39.
12. Gao J., Yang G., Pi R., Li R., Wang P., Zhang H., Le K., Chen S., Liu P. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl. Res. 2008, 151(2):79-87.
13. Gheorghiade M., De Luca L., Bonow R.O. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am. J. Cardiol. 2005, 96(Suppl. 12A):3L-9L.
14. Gupta S., Young D., Sen S. Inhibition of NF-κB induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2005, 289(1):H20-H29.
15. Hamid S.A., Bower H.S., Baxter G.F. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Am. J. Physiol. Heart Circ. Physiol. 2007, 292(6):H2598-H2606.
16. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Kaibuchi K., Takeshita A. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ. Res. 2004, 94(1):46-52.
17. Hattori T., Shimokawa H., Higashi M., Hiroki J., Mukai Y., Tsutsui H., Kaibuchi K., Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109(18):2234-2239.
18. Huang Y., Johnson K.R., Norris J.S., Fan W. Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 2000, 60(16):4426-4432.
19. Hydock D.S., Wonders K.Y., Schneider C.M., Hayward R. Voluntary wheel running in rats receiving doxorubicin: effects on running activity and cardiac myosin heavy chain. Anticancer Res. 2009, 29(11):4401-4407.
20. Kalyanaraman B., Joseph J., Kalivendi S., Wang S., Konorev E., Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell. Biochem. 2002, 234-235(1-2):119-124.
21. Kim T., Yoon J., Cho H., Lee W.B., Kim J., Song Y.H., Kim S.N., Yoon J.H., Kim-Ha J., Kim Y.J. Downregulation of lipopolysaccharide response in Drosophila by negative crosstalk between the AP1 and NF-κB signaling modules. Nat. Immunol. 2005, 6(2):211-218.
22. Kojima S., Icho T., Hayashi M., Kajiwara Y., Kitabatake K., Kubota K. Inhibitory effect of 5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J. Pharmacol. Exp. Ther. 1993, 266(3):1699-1704.
23. Koshikawa M., Mukoyama M., Mori K., Suganami T., Sawai K., Yoshioka T., Nagae T., Yokoi H., Kawachi H., Shimizu F., Sugawara A., Nakao K. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J. Am. Soc. Nephrol. 2005, 16(9):2690-2701.
24. Lai J., Hsieh C., Chang Z. Caspase activation during phorbol ester-induced apoptosis requires ROCK-dependent myosin-mediated contraction. J. Cell Sci. 2003, 116(17):3491-3501.
25. Li W., Zhang X., Olumi A.F. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP (L). Cancer Res. 2007, 67(5):2247-2255.
26. Li J.Q., Li W.M., Yue L., Zhao J.Y., Kong Y.H., Guo H., Xue J.Y., Sheng L., Gong Y.T., Xue H.J. Altered expression of ADAMTS-1 and its inhibitor in rats with chronic heart failure induced by adriamycin. Heart 2010, 96:A47.
27. Little G.H., Saw A., Bai Y., Dow J., Marjoram P., Simkhovich B., Leeka J., Kedes L., Kloner R.A., Poizat C. Critical role of nuclear calcium/calmodulin-dependent protein kinase II σB in cardiomyocyte survival in cardiomyopathy. J. Biol. Chem. 2009, 284(37):24857-24868.
28. Marinissen M.J., Chiariello M., Tanos T., Bernard O., Narumiya S., Gutkind J.S. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol. Cell 2004, 14(1):29-41.
29. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 2003, 41(1):15-19.
30. Morabito A., Gattuso D., Stani S.C., Fanelli M., Ferrau F., De Sio L., Castellana M.A., Lorusso V., Priolo D., Vitale S., Sarmiento R., Lo V.S., Mariani L., Gasparini G. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res. Treat. 2004, 86(3):249-258.
31. Nithipongvanitch R., Ittarat W., Velez J.M., Zhao R., St C.D., Oberley T.D. Evidence for p53 as guardian of the cardiomyocyte mitochondrial genome following acute adriamycin treatment. J. Histochem. Cytochem. 2007, 55(6):629-639.
32. Novitzky N., Thomas V., Abrahams L., du Toit C., McDonald A. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Am. J. Hematol. 2004, 76(4):319-329.
33. Okada M., Kikuzuki R., Harada T., Hori Y., Yamawaki H., Hara Y. Captopril attenuates matrix metalloproteinase-2 and -9 in monocrotaline-induced right ventricular hypertrophy in rats. J. Pharmacol. Sci. 2008, 108(4):487-494.
34. Okada M., Harada T., Kikuzuki R., Yamawaki H., Hara Y. Effects of telmisartan on right ventricular remodeling induced by monocrotaline in rats. J. Pharmacol. Sci. 2009, 111(2):193-200.
35. Otsuka T., Ibuki C., Suzuki T., Ishii K., Yoshida H., Kodani E., Kusama Y., Atarashi H., Kishida H., Takano T., Mizuno K. Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron. Artery Dis. 2008, 19(2):105-110.
36. 2-induced oxidative stress in neonatal rat cardiac myocytes. J. Biol. Chem. 2009, 284(40):27195-27210.
37. Ray N., Kuwahara M., Takada Y., Maruyama K., Kawaguchi T., Tsubone H., Ishikawa H., Matsuo K. C-Fos suppresses systemic inflammatory response to endotoxin. Int. Immunol. 2006, 18(5):671-677.
38. Rouet-Benzineb P., Gontero B., Dreyfus P., Lafuma C. Angiotensin II induces nuclear factor-κB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J. Mol. Cell. Cardiol. 2000, 32(10):1767-1778.
39. Sabbah H.N., Sharov V.G., Gupta R.C., Mishra S., Rastogi S., Undrovinas A.I., Chaudhry P.A., Todor A., Mishima T., Tanhehco E.J., Suzuki G. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ. Res. 2003, 93(11):1095-1101.
40. Schmitz I., Weyd H., Krueger A., Baumann S., Fas S.C., Krammer P.H., Kirchhoff S. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIP short. J. Immunol. 2004, 172(4):2194-2200.
41. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4(5):E131-E136.
42. Shimokawa H., Hiramori K., Iinuma H., Hosoda S., Kishida H., Osada H., Katagiri T., Yamauchi K., Yui Y., Minamino T., Nakashima M., Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J. Cardiovasc. Pharmacol. 2002, 40(5):751-761.
43. Si K., Liu J., He L., Li X., Gou W., Liu C., Li X. Caulophine protects cardiomyocytes from oxidative and ischemic injury. J. Pharmacol. Sci. 2010, 113(4):368-377.
44. Simpson P.C. Proto-oncogenes and cardiac hypertrophy. Annu. Rev. Physiol. 1989, 51:189-202.
45. Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 1998, 339(13):900-905.
46. Taoufiq Z., Gay F., Balvanyos J., Ciceron L., Tefit M., Lechat P., Mazier D. Rho kinase inhibition in severe malaria: thwarting parasite-induced collateral damage to endothelia. J. Infect. Dis. 2008, 197(7):1062-1073.
47. Toshima Y., Satoh S., Ikegaki I., Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000, 31(9):2245-2250.
48. Wang Y., Madanat F.F., Kimball J.C., Gleiser C.A., Ali M.K., Kaufman M.W., van Eys J. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res. 1980, 40(4):1022-1027.
49. 2+ currents in cardiac myocytes. Am. J. Physiol. Heart Circ. Physiol. 2005, 288(2):H650-H659.
50. Zhang Y.M., Bo J., Taffet G.E., Chang J., Shi J., Reddy A.K., Michael L.H., Schneider M.D., Entman M.L., Schwartz R.J., Wei L. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 2006, 20(7):916-925.
51. Zhang J., Li X.X., Bian H.J., Liu X.B., Ji X.P., Zhang Y. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin. Chim. Acta 2009, 401(1-2):76-80.
52. Zhang J., Bian H.J., Li X.X., Liu X.B., Sun J.P., Li N., Zhang Y., Ji X.P. ERK-MAPK signaling opposes Rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. Mol. Med. 2010, 16(7-8):307-315.